Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction
The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
AIMS: Elevated non-fasting triglycerides mark elevated levels of remnant cholesterol. Using a Mendelian randomization approach, we tested whether genetically increased remnant cholesterol in hypertriglyceridaemia due to genetic variation in the apolipoprotein A5 gene (APOA5) associates with an increased risk of myocardial infarction (MI). METHODS AND RESULTS: We resequenced the core promoter and coding regions of APOA5 in individuals with the lowest 1% (n = 95) and highest 2% (n = 190) triglyceride levels in the Copenhagen City Heart Study (CCHS, n = 10 391). Genetic variants which differed in frequency between the two extreme triglyceride groups (c.-1131T > C, S19W, and c.*31C > T; P-value: 0.06 to <0.001), thus suggesting an effect on triglyceride levels, were genotyped in the Copenhagen General Population Study (CGPS), the CCHS, and the Copenhagen Ischemic Heart Disease Study (CIHDS), comprising a total of 5705 MI cases and 54 408 controls. Genotype combinations of these common variants associated with increases in non-fasting triglycerides and calculated remnant cholesterol of, respectively, up to 68% (1.10 mmol/L) and 56% (0.40 mmol/L) (P < 0.001), and with a corresponding odds ratio for MI of 1.87 (95% confidence interval: 1.25-2.81). Using APOA5 genotypes in instrumental variable analysis, the observational hazard ratio for a doubling in non-fasting triglycerides was 1.57 (1.32-2.68) compared with a causal genetic odds ratio of 1.94 (1.40-1.85) (P for comparison = 0.28). For calculated remnant cholesterol, the corresponding values were 1.67(1.38-2.02) observational and 2.23(1.48-3.35) causal (P for comparison = 0.21). CONCLUSION: These data are consistent with a causal association between elevated levels of remnant cholesterol in hypertriglyceridaemia and an increased risk of MI. Limitations include that remnants were not measured directly, and that APOA5 genetic variants may influence other lipoprotein parameters.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Observational cohorts demonstrate that higher TG and remnant cholesterol predict cardiovascular events independently of LDL-C, while Mendelian randomization analyses confirm a causal relationship between lifelong TRL elevation and ASCVD.”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [62]
In the citing paper
“Epidemiological and Mendelian randomization studies have also pointed toward a causal role of elevated triglycerides in atherosclerosis due to an elevation of remnant cholesterol particles (7-9).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [8]
In the citing paper
“Elevated triglycerides are associated with an increase in remnant cholesterol, a decrease in high-density lipoprotein cholesterol (HDL-C), and an increase in LDL particles with a change in morphology to small, dense particles.”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [8]
In the citing paper
“Recent systematic studies comparing fasting and non-fasting samples have suggested that the difference is small for most lipid parameters [85,94-100].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [94]
In the citing paper
“Non-HDL-C also includes the atherogenic TG-rich lipoproteins (VLDL, IDL and remnants), which is essential considering the recent information from genome-wide association studies (GWASs) and Mendelian randomization 76,86 - 89 supporting TGs and remnant particles as causative factors in atherogenesis.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [76]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
Antman, E., Bassand, J.-P., Klein, W., Ohman, M., Lopez Sendon, J. L., Rydén, L., Simoons, M., & Tendera, M. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00804-4 · Cited by 4,821
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Clinical Investigation Group: Paul W. Armstrong, C. (., Global Perspective Group: Philip A. Poole-Wilson, C. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,230
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Interaction revisited: the difference between two estimates.
Altman, D. G., & Bland, J. M. (2003) · BMJ · doi:10.1136/bmj.326.7382.219 · Cited by 3,203 · cited 1×
“Causal genetic estimates from instrumental variable analysis were compared with an observed risk of MI from observational epidemiology using the Altman and Bland method.(29)”
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Task Force Members, Thygesen, K., Alpert, J. S., White, H. D., Biomarker Group, Jaffe, A. S., Apple, F. S., Galvani, M., Katus, H. A., Newby, L. K., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm355 · Cited by 2,541
Research works printed but not linked: 1
- 2001, Type III hyperlipoproteinemia (dyslipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism, 2835
Cited by
Items 101–200 of 506
Remnant Cholesterol is an Independent Predictor of New-Onset Diabetes: A Single-Center Cohort Study
Xie, G., Zhong, Y., Yang, S., & Zou, Y. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s341285 · Cited by 71
The Impact of the Blood Lipids Levels on Arterial Stiffness
Baba, M., Mariș, M. I., Jianu, D., Luca, C. T., Stoian, D. L., & Mozos, I. M. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10030127 · Cited by 73
Premature myocardial infarction is strongly associated with increased levels of remnant cholesterol
Goliasch, G., Wiesbauer, F., Blessberger, H., Demyanets, S., Wojta, J., Huber, K., Maurer, G., Schillinger, M., & Speidl, W. S. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.08.009 · Cited by 75
Nordestgaard, L. T., Christoffersen, M., Afzal, S., Nordestgaard, B. G., Tybjærg-Hansen, A., & Frikke-Schmidt, R. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvaa269 · Cited by 60
Self-citationYu, D., Wang, Z., Zhang, X., Qu, B., Cai, Y., Ma, S., Zhao, Z., & Simmons, D. S. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab533 · Cited by 71
Lin, A., Nerlekar, N., Rajagopalan, A., Yuvaraj, J., Modi, R., Mirzaee, S., Munnur, R. K., Seckington, M., Doery, J. C., Seneviratne, S., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.02.019 · Cited by 64
Kolovou, G. D., Watts, G. F., Mikhailidis, D. P., Pérez-Martínez, P., Mora, S., Bilianou, H., Panotopoulos, G., Katsiki, N., Ooi, T. C., Lopez-Miranda, J., et al. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190507110519 · Cited by 61
Self-citationHypertriglyceridemia and Cardiovascular Diseases: Revisited
Han, S. H., Nicholls, S. J., Sakuma, I., Zhao, D. H., & Koh, K. K. (2016) · Korean Circulation Journal · doi:10.4070/kcj.2016.46.2.135 · Cited by 70
Toth, P. P., Philip, S., HULL, M. L., & Granowitz, C. B. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.03.028 · Cited by 64
Toth, P. P., Fazio, S., Wong, N. D., HULL, M. L., & Nichols, G. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13921 · Cited by 71
Hansen, S. E. J., Madsen, C. M., Varbo, A., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.08.016 · Cited by 57
Self-citationKoopal, C., Retterstøl, K., Sjouke, B., Hovingh, G. K., Ros, E., de Graaf, J., Dullaart, R. P. F., Bertolini, S., & Visseren, F. L. J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.02.046 · Cited by 58
Angiopoietin-2 blocking antibodies reduce early atherosclerotic plaque development in mice
Theelen, T. L., Lappalainen, J. P., Sluimer, J. C., Gurzeler, E., Cleutjens, J. P., Gijbels, M. J., Biessen, E. A. L., Daemen, M. J. A. P., Alitalo, K., & Ylä-Herttuala, S. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.05.018 · Cited by 58
Triglycerides and ASCVD risk reduction: recent insights and future directions
Hussain, A., Ballantyne, C. M., Saeed, A., & Virani, S. S. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00846-8 · Cited by 57
Remnant cholesterol and ischemic heart disease
Varbo, A., & Nordestgaard, B. G. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000093 · Cited by 55
Self-citationTriglycerides, Atherosclerosis, and Cardiovascular Outcome Studies: Focus on Omega-3 Fatty Acids
Handelsman, Y., & Shapiro, M. D. (2016) · Endocrine Practice · doi:10.4158/ep161445.ra · Cited by 60
Metabolic syndrome and its predictors in an urban population in Kenya: A cross sectional study
Omuse, G., Maina, D., Hoffman, M., Mwangi, J., Wambua, C., Kagotho, E., Amayo, A., Ojwang, P., Premji, Z. G., Ichihara, K., et al. (2017) · BMC Endocrine Disorders · doi:10.1186/s12902-017-0188-0 · Cited by 56
Target Populations for Novel Triglyceride-Lowering Therapies
Nordestgaard, A. T., Tybjærg-Hansen, A., Mansbach, H., Kersten, S., Nordestgaard, B. G., & Rosenson, R. S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.02.035 · Cited by 54
Self-citationArca, M., Borghi, C., Pontremoli, R., De Ferrari, G. M., Colivicchi, F., Desideri, G., & Temporelli, P. L. (2018) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.11.001 · Cited by 52
Inflammatory Links Between Hypertriglyceridemia and Atherogenesis
Peng, X., & Wu, H. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01006-w · Cited by 54
Wang, K., Wang, R., Yang, J., Liu, X., Shen, H., Sun, Y., Zhou, Y., Fang, Z. A., & Ge, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.913869 · Cited by 57
Guan, B., Wang, A., & Xu, H. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01927-z · Cited by 54
Hypertriglyceridemia: new approaches in management and treatment
Wolska, A., Yang, Z.-H., & Remaley, A. T. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000710 · Cited by 49
Würtz, P., Kangas, A. J., Soininen, P., Lehtimäki, T. J., Kähönen, M. A. P., Viikari, J. S. A., Raitakari, O. T., Järvelin, M., Smith, G. D., & Ala‐Korpela, M. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.085 · Cited by 52
Sun, H., Zhu, W., Liu, J., An, Y., Wang, Y., & Wang, G. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac523 · Cited by 53
Toth, P. P., Hamon, S. C., Jones, S. R., Martin, S. S., Joshi, P. H., Kulkarni, K. R., Banerjee, P., Hanotin, C., Roth, E. M., & McKenney, J. M. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0197-4 · Cited by 50
10-Year Comparative Follow-up of Familial versus Multifactorial Chylomicronemia Syndromes
Belhassen, M., Van Ganse, E., Nolin, M., Bérard, M., Bada, H., Bruckert, E., Krempf, M., Rebours, V., Valero, R., & Moulin, P. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa838 · Cited by 47
Gao, S., Xu, H., Ma, W., Yuan, J., & Yu, M. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024366 · Cited by 47
Shao, Q., Yang, Z., Wang, Y., Li, Q., Han, K., Liang, J., Shen, H., Liu, X., Zhou, Y., Ma, X., et al. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63397 · Cited by 49
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I. M., Backer, G. D., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0157 · Cited by 62
Si, S., Hou, L., Chen, X., Li, W., Liu, X., Liu, C., Li, Y., Yuan, T., Li, J., Wang, B., et al. (2021) · Journal of Epidemiology · doi:10.2188/jea.je20200305 · Cited by 55
Berman, A. N., & Blankstein, R. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1175-z · Cited by 55
The Regulation of Triacylglycerol Metabolism and Lipoprotein Lipase Activity
Wen, Y., Chen, Y., & Konrad, R. J. (2022) · Advanced Biology · doi:10.1002/adbi.202200093 · Cited by 53
Djekic, D., Pinto, R. C., Repsilber, D., Hyötyläinen, T., & Henein, M. Y. (2019) · Vascular Health and Risk Management · doi:10.2147/vhrm.s202344 · Cited by 50
Triglyceride and cardiovascular risk: A critical appraisal
Singh, A. K., & Singh, R. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.183460 · Cited by 51
ApoB48 as an Efficient Regulator of Intestinal Lipid Transport
Lo, C. C., & Coschigano, K. T. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00796 · Cited by 47
Heidemann, B. E., Koopal, C., Bots, M. L., Asselbergs, F. W., Westerink, J., & Visseren, F. L. J. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.08.030 · Cited by 48
Dai, W., Zhang, Z., Yao, C., & Zhao, S. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1166-5 · Cited by 47
Galli, M., Abbate, A., Bonaca, M. P., Crea, F., Forte, M., Frati, G., Gaudino, M. F. L., Gibson, C. M., Gorog, D. A., Mehran, R., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01249-z · Cited by 52
Remnant cholesterol in patients admitted for acute coronary syndromes
Cordero, A., Álvarez, B. Á., Escribano, D., García‐Acuña, J. M., Cid-Álvarez, B. A., Rodríguez‐Mañero, M., Quintanilla, M. A., Agra-Bermejo, R., Zuazola, P., & González‐Juanatey, J. R. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac286 · Cited by 48
Bays, H. E., Ballantyne, C. M., Doyle, R. T., Juliano, R. A., & Philip, S. (2016) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2016.07.007 · Cited by 43
Ooi, E. M. M., Afzal, S., & Nordestgaard, B. G. (2014) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.113.000416 · Cited by 44
Self-citationJohansen, M. Ø., Vedel‐Krogh, S., Nielsen, S. F., Afzal, S., Smith, G. D., & Nordestgaard, B. G. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315639 · Cited by 45
Self-citationThe metabolic and pharmacologic bases for treating atherogenic dyslipidaemia
Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.10.001 · Cited by 50
Dittrich, J., Beutner, F., Teren, A., Thiery, J., Burkhardt, R., Scholz, M., & Ceglarek, U. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.11.006 · Cited by 41
Johansen, M. Ø., Nielsen, S. F., Afzal, S., Vedel‐Krogh, S., Smith, G. D., & Nordestgaard, B. G. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa290 · Cited by 46
Self-citationGabani, M., Shapiro, M. D., & Toth, P. P. (2023) · European Cardiology Review · doi:10.15420/ecr.2023.16 · Cited by 33
Hong, L.-F., Yan, X.-N., Lu, Z.-H., Fan, Y., Ye, F., Wu, Q., Luo, S.-H., Yang, B., & Li, J. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0410-0 · Cited by 42
Campanella, A., Iacovazzi, P. A., Misciagna, G., Bonfiglio, C., Mirizzi, A., Franco, I., Bianco, A., Sorino, P., Caruso, M. G., Cisternino, A. M., et al. (2020) · Nutrients · doi:10.3390/nu12061674 · Cited by 43
for the BIP Study Group, Arbel, Y., Klempfner, R., Erez, A., Goldenberg, I., Benzekry, S., Shlomo, N., Fisman, E. Z., & Tenenbaum, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0332-6 · Cited by 40
Genetic insights into cardiometabolic risk factors.
Whitfield, J. B. (2014) · Europe PMC (PubMed Central) · Cited by 53
Jørgensen, P. G., Jensen, M. T., Biering‐Sørensen, T., Møgelvang, R., Galatius, S., Fritz‐Hansen, T., Rossing, P. R., Vilsbøll, T., & Jensen, J. S. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0454-x · Cited by 48
Low High-Density Lipoprotein Cholesterol to Monitor Long-Term Average Increased Triglycerides
Langsted, A., Jensen, A. M. R., Varbo, A., & Nordestgaard, B. G. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz265 · Cited by 37
Self-citationDjekic, D., Shi, L. S., Calais, F., Carlsson, F., Landberg, R., Hyötyläinen, T., & Fröbert, O. (2020) · Nutrients · doi:10.3390/nu12113586 · Cited by 38
Remnant cholesterol is associated with cardiovascular mortality
Zhang, K., Qi, X., Zhu, F., Dong, Q., Gou, Z., Wang, F., Xiao, L., Li, M., Chen, L., Wang, Y., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.984711 · Cited by 42
Guan, X., Wu, S., Yang, X., Han, X., Yang, Y., Li, X., Waleed, K. B., Du, Y., Zhan, S., Liu, Y., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.31149 · Cited by 40
Allergic ocular disorders: a spectrum of diseases.
Ehlers, W. H., & Donshik, P. C. (1992) · PubMed · Cited by 41
Kegulian, N. C., Ramms, B., Horton, S. B., Trenchevska, O., Nedelkov, D., Graham, M. J., Lee, R. G., Esko, J. D., Yassine, H. N., & Gordts, P. L. S. M. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312723 · Cited by 38
Clinical characteristics of Japanese patients with severe hypertriglyceridemia
Tada, H., Kawashiri, M., Nakahashi, T., Yagi, K., Chujo, D., Ohbatake, A., Mori, Y., Mori, S., Kometani, M., Fujii, H., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.05.004 · Cited by 35
Lorenzatti, A. J., Monsalvo, M. L., López, J. A. G., Wang, H., & Rosenson, R. S. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01287-6 · Cited by 34
Ghafouri, K. J., Cooney, J., Bedford, D. K., Wilson, J., CASLAKE, M. J., & Gill, J. M. R. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1196 · Cited by 40
Kofink, D., Eppinga, R. N., van Gilst, W. H., Bakker, S. J. L., Dullaart, R. P. F., van der Harst, P., & Asselbergs, F. W. (2017) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.117.001759 · Cited by 35
Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
Musunuru, K. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-044918 · Cited by 34
Jackson, W. D., Weinrich, T. W., & Woollard, K. J. (2016) · Scientific Reports · doi:10.1038/srep20038 · Cited by 36
Aaseth, E., Halvorsen, S., Helseth, R., & Gravning, J. A. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf104 · Cited by 32
Remnant cholesterol in atherosclerotic cardiovascular disease: A systematic review and meta-analysis
Delialis, D., Georgiopoulos, G. A., Aivalioti, E., Konstantaki, C., Oikonomou, E., Bampatsias, D., Mavraganis, G., Vardavas, C. I., Liberopoulos, E. N., Stellos, K., et al. (2023) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2023.04.007 · Cited by 33
Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects
Mijares, A. H., Ascaso, J. F., Blasco, M., Brea, Á., Díaz, Á., Mantilla, T., Pedro‐Botet, J., Pintó, X., & Millán, J. (2019) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2019.02.002 · Cited by 37
Gonna, H., & Ray, K. K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13691 · Cited by 33
Schmidt, A. F., Joshi, R., Gordillo‐Marañón, M., Drenos, F., Charoen, P., Giambartolomei, C., Bis, J. C., Gaunt, T. R., Hughes, A. D., Lawlor, D. A., et al. (2023) · Communications Medicine · doi:10.1038/s43856-022-00234-0 · Cited by 33
Hypercoagulation and elevation of blood triglycerides are characteristics of Kawasaki disease
Chen, X., Zhao, Z., Li, L., Chen, X., Xu, H., Lou, J., Li, L., Du, L., & Xie, C. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0167-2 · Cited by 31
Apolipoprotein B - An ideal biomarker for atherosclerosis?
Singh, K., & Prabhakaran, D. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2023.12.001 · Cited by 30
Mendelian randomization studies on atherosclerotic cardiovascular disease: evidence and limitations
Hu, Q., Hao, P., Liu, Q., Dong, M., Gong, Y., Zhang, C., & Zhang, Y. (2019) · Science China Life Sciences · doi:10.1007/s11427-019-9537-4 · Cited by 32
Liu, J., Fan, F., Liu, B., Li, K., Jiang, Y., Jia, J., Chen, C., Zheng, B., & Zhang, Y. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.993097 · Cited by 32
Jin, Q., Lau, E. S. H., Luk, A. O. Y., Tam, C. H. T., Ozaki, R., Lim, C. K. P., Wu, H., Chow, E., Kong, A. P. S., Lee, H. M., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06108-5 · Cited by 32
Pham, D. D., Bruelle, C., Thi, H., Pajanoja, C., Jin, C., Srinivasan, V., Olkkonen, V. M., Eriksson, O., Jauhiainen, M., Lalowski, M. M., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1758-z · Cited by 30
[Incisional hernia after surgery for abdominal aortic aneurysm].
Augestad, K. M., Wilsgaard, T., & Solberg, S. K. (2002) · Tidsskrift for Den Norske Laegeforening · Cited by 41
The Remnants of Residual Risk∗
Joshi, P. H., Martin, S. S., & Blumenthal, R. S. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.543 · Cited by 31
Kexin, W., Yaodong, D., Wen, G., Rui, W., Jiaxin, Y., Xiaoli, L., Hua, S., & Hailong, G. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.740596 · Cited by 28
Remnant Cholesterol and Residual Risk of Atherosclerotic Cardiovascular Disease
Li, X., Li, Z.-F., & Wu, N. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm25985 · Cited by 30
Life-Course Implications of Pediatric Risk Factors for Cardiovascular Disease
Falkner, B. E., & Gidding, S. S. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.02.001 · Cited by 29
Chen, X., & Li, L. (2023) · Cureus · doi:10.7759/cureus.44202 · Cited by 31
Correlation between remnant cholesterol and hyperuricemia in American adults
Zhou, X., Weng, X., Xu, J., & Wang, W. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02167-0 · Cited by 28
Tada, H., Nomura, A., Yoshimura, K., Itoh, H., Komuro, I., Yamagishi, M., Takamura, M., & Kawashiri, M. (2020) · Circulation Journal · doi:10.1253/circj.cj-19-0981 · Cited by 29
Zhou, L., Liu, J., An, Y., Wang, Y., & Wang, G. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.898305 · Cited by 31
Deprince, A., Hennuyer, N., Kooijman, S., Pronk, A. C. M., Baugé, E., Liénard, V., Verrijken, A., Dirinck, E. L., Vonghia, L., Woitrain, E., et al. (2022) · Hepatology · doi:10.1002/hep.32631 · Cited by 30
New approaches to triglyceride reduction: is there any hope left?
Filtz, A., Parihar, S., Greenberg, G. S., Park, C. M., Scotti, A., Lorenzatti, D., Badimon, J. J., Soffer, D. E., Toth, P. P., Lavie, C. J., et al. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100648 · Cited by 26
“…participants within the Copenhagen General Population Study, Copenhagen City Heart Study, and Copenhagen Ischemic Heart Disease Study, showed that higher levels of TG and TRL increased the risk of MI (OR 1.87; 95 % CI 1.25-2.81) regardless of age, sex, smoking, hypertension and diabetes [23].”
BackgroundInfluentialRen, Q.-W., Teng, T. K., Ouwerkerk, W., Tse, Y.-K., Tsang, C. T., Wu, M., Tse, H., Voors, A. A., Tromp, J., Lam, C. S. P., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56790-1 · Cited by 27
Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs
KONES, R. J., & Rumana, U. (2015) · Drugs · doi:10.1007/s40265-015-0429-3 · Cited by 27
Koohi, F., Khalili, D., Mansournia, M. A., Hadaegh, F., & Soori, H. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02966-4 · Cited by 27
Wang, Z., Li, M., Xie, J., Gong, J., & Liu, N. (2021) · Journal of Clinical Hypertension · doi:10.1111/jch.14384 · Cited by 27
Wang, Y.-X., Wang, A., Ye, Y.-N., Gao, Z., Tang, X., Yan, L., Wan, Q., Wang, W., Luo, Z., Qin, G., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0863-8 · Cited by 27
Xiang, Q., Tian, F., Lin, Q., Du, X., Zhang, S., Gui, Y., Guo, L., Xu, J. R., Zhu, L., Wen, T., et al. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.09.020 · Cited by 28
Moderate Alcohol Consumption and Triglyceridemia
Kovář, J., & Zemánková, K. (2015) · Physiological Research · doi:10.33549/physiolres.933178 · Cited by 28
The role of triglycerides in the origin and progression of atherosclerosis
Padró, T., Muñoz‐García, N., & Badimón, L. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.02.007 · Cited by 30
Miller, M. J., Tokgözoğlu, L. S., Parhofer, K. G., Handelsman, Y., Leiter, L. A., Landmesser, U., Brinton, E. A., & Catapano, A. L. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2103541 · Cited by 26
Sibilitz, K. L., Benn, M., & Nordestgaard, B. G. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.08.040 · Cited by 25
Self-citationVijayaraghavan, K., Baum, S. J., Desai, N. R., & Voyce, S. J. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1308173 · Cited by 26
Inhibition of ApoCIII: the next PCSK9?
Moens, S. J. B., van Capelleveen, J. C., & Stroes, E. S. G. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000130 · Cited by 25
Current pharmacotherapeutic options for primary dyslipidemia in adults
Cicero, A. F. G., Landolfo, M., Ventura, F., & Borghi, C. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1604687 · Cited by 26
Shao, Q., Ma, X., Yang, Z., Li, Q.-X., Wang, Y., Liang, J., Shen, H., Liu, X., Zhou, Y., Shi, D., et al. (2022) · PubMed Central · doi:10.11909/j.issn.1671-5411.2022.06.001 · Cited by 29
Metadata
- Authors
- Jørgensen, A. B., Frikke-Schmidt, R., West, A. S., Grande, P., Nordestgaard, B. G., & Tybjærg-Hansen, A.
- Affiliations
- University of Copenhagen (DK)
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-12-17
- Volume
- 34
- Issue
- 24
- Pages
- 1826-1833
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2040770080
- Cited by
- 501
- References
- 60
- Citations by year
- 2026: 28 · 2025: 53 · 2024: 48 · 2023: 40 · 2022: 51 · 2021: 45 · 2020: 41 · 2019: 39 · 2018: 26 · 2017: 34 · 2016: 31 · 2015: 30 · 2014: 20 · 2013: 11
- FWCI
- 19.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- remnant cholesterol, hypertriglyceridemia, myocardial infarction, APOA5, genetic variants, causal risk factors, remnant lipoproteins, Copenhagen City Heart Study, Copenhagen General Population Study, instrumental variables, Mendelian randomization
- MeSH terms
- Apolipoprotein A-V, Adult, Aged, Aged, 80 and over, Apolipoproteins A, Cholesterol, Female, Genotype, Humans, Lipoproteins, Male, Middle Aged, Myocardial Infarction, Promoter Regions, Genetic, Prospective Studies, Risk Factors, Triglycerides, Hypertriglyceridemia, Linkage Disequilibrium, Case-Control Studies, Polymorphism, Single Nucleotide, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.